modelG04BA03
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | CalciumChloride | |
| ATC code: | G04BA03 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 0.4 | L/kg/h |
| other parameters in model implementation | ||
Calcium chloride is an inorganic salt used primarily to treat hypocalcemia, hyperkalemia, hypomagnesemia, and as an adjunct in cardiac resuscitation during emergencies such as cardiac arrest. It is administered intravenously and is not commonly used orally due to poor tolerability. Calcium chloride is approved for use in medical emergencies where rapid calcium elevation is needed.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adult individuals, as specific clinical pharmacokinetic studies for calcium chloride are lacking. Given that calcium chloride fully dissociates and delivers calcium ions rapidly into the circulation after IV administration, a one-compartment model is assumed.
References
Ansari, JR, et al., & Shafer, SL (2025). Bioequivalence and Pharmacokinetics of Intravenous Calcium during Cesarean Delivery. Anesthesiology 142(1) 121–131. DOI:10.1097/ALN.0000000000005248 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39361822
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
Ansari, JR, et al., & Riley, E (2022). Calcium chloride for the prevention of uterine atony during cesarean delivery: A pilot randomized controlled trial and pharmacokinetic study. Journal of clinical anesthesia 80 110796–None. DOI:10.1016/j.jclinane.2022.110796 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35447502
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)